Free Widgets | Feedback 
Live Share Markets - Appuonline.com


Updated:18 Oct 2017 03:31:00 PM(IST)

Investor Tool

My Stockwatch 

RELIANCE 914.50 [ +4.59% ]TCS 2586.60 [ -0.31% ]

Sensex32584.35
-24.81 -0.08%

Nifty10210.85
-23.60 -0.23%

Midcap16115.98
1.48 0.01%

Smallcap17063.39
-2.76 -0.02%


Bse Corporate Announcements Back
Lupin settles ongoing litigation with Medicis
Lupin settles ongoing litigation with Medicis Over generic versions of SOLODYN Lupin has announced that the company and its subsidiary, Lupin Pharmaceuticals, Inc have settled all ongoing litigation over SOLODYN (minocycline HCI, USP) extended release tablets with Medicis Pharmaceutical Corporation. The settlement entitles Lupin to sell its generic versions of SOLODYN in 45mg, 90mg, and 135mg strengths under a license from Medicis commencing November 2011 or earlier under certain conditions. The settlement also entitles Lupin to sell its generic versions of SOLODYN in 65mg and 115mg strengths under a license from Medicis effective in February 2018 or earlier under certain conditions. In addition, the settlement entitles Lupin to sell its generic versions of SOLODYN in 55mg, 80mg and 105mg strengths under a license from Medicis effective in February 2019 or earlier under certain conditions. The company made this announcement after the trading hours on 25 July 2011.

Market on Mobile
























Site Map  •  Mobile  •  Companies  •  Learning Centre  •  Insurance •  About  •  Contact us  •  Disclaimer
© appuonline.com